AstraZeneca Coronavirus Vaccine Clinical Trial Paused

According to an article in Stat, AstraZeneca (NYSE: AZN) has paused the U.S. clinical trial of its coronavirus vaccine, AZD1222, after a serious possible adverse event arose in a patient enrolled in a clinical trial testing AZD122 in the U.K. At this point, the nature of the adverse event is not known, and it isn't clear whether it was caused by AZD122. In addition to the 30,000-participant U.S. study announced last week, AstraZeneca is also running clinical trials in the U.K., Brazil, and South Africa.